Biogen (BIIB) said, for 2026, it now expects adjusted EPS in a range of $14.25 to $15.25, revised from prior guidance range of $15.25 to $16.25. Biogen updated its guidance to reflect an approximately $1.00 impact from acquired IPR&D charges resulting from ongoing business development activities to support Biogen's growth strategy. This comprises approximately $0.20 recorded in the first quarter and approximately $0.80 expected in the second quarter. The updated guidance excludes the anticipated Apellis transaction.
Biogen said its fiscal 2026 total revenue is expected to decline by a mid-single digit percentage as compared to 2025 as further declines in multiple sclerosis product revenue, excluding VUMERITY, are expected to be partially offset by increases in revenue from growth products. The company expects MS product revenue, excluding VUMERITY, to decline by a mid-teen percentage. Biosimilars are expected to continue to decline by low double-digit percentage.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.